GRAIL, Inc. (GRAL)
60.42
+1.83
(+3.12%)
USD |
NASDAQ |
Jun 11, 11:09
GRAIL Debt to Equity Ratio : 0.0204 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.0204 |
| December 31, 2025 | 0.0213 |
| September 30, 2025 | 0.0262 |
| June 30, 2025 | 0.0269 |
| March 31, 2025 | 0.0266 |
| December 31, 2024 | 0.0272 |
| September 30, 2024 | 0.0279 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.0282 |
| March 31, 2024 | 0.0214 |
| December 31, 2023 | 0.0231 |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| September 30, 2020 | 0.0967 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Apogee Therapeutics, Inc. | 0.0064 |
| Evommune, Inc. | 0.0299 |
| Arrowhead Pharmaceuticals, Inc. | 2.237 |
| Oncolytics Biotech, Inc. | -0.099 |
| Sangamo Therapeutics, Inc. | -1.020 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.803B |
| Total Liabilities (Quarterly) | 302.79M |
| Shareholders Equity (Quarterly) | 2.501B |
| Current Ratio | 11.74 |
| Net Debt Paydown Yield | 0.16% |